30Jun
Healthcare M&A prospers, despite fall in deal activity
The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis - Although pharma, medical and biotech (PMB) M&A deal value for Q1 2020 came in at US$39.3 billion, 78% below the year before, this was primarily due to the outsized US$87.8 billion deal between Bristol-Myers Squibb and Celgene in early 2019....
By:
White & Case LLP
Related
As we advised in June 2019, there was an unprecedented decision by Justice Melissa Crane of the New ...
Read More >
Until recently, state and federal enforcers shared a common outlook in their approach and goals for ...
Read More >
The U.S. Fish and Wildlife Service and National Marine Fisheries Service issued a set of three new f...
Read More >
Continuing a busy summer of changes, on July 29, 2019, Governor Cuomo signed an amendment to New Yor...
Read More >
Sometimes. The CCPA states that a business should disclose any information that it is required to d...
Read More >
Seyfarth Synopsis: Once effective, the anti-discrimination and retaliation provisions of the NYC Hum...
Read More >